CN109907170A - A kind of compound anti-coagulants of animal blood - Google Patents
A kind of compound anti-coagulants of animal blood Download PDFInfo
- Publication number
- CN109907170A CN109907170A CN201910176976.7A CN201910176976A CN109907170A CN 109907170 A CN109907170 A CN 109907170A CN 201910176976 A CN201910176976 A CN 201910176976A CN 109907170 A CN109907170 A CN 109907170A
- Authority
- CN
- China
- Prior art keywords
- coagulants
- sodium
- compound anti
- blood
- animal blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a kind of compound anti-coagulants of animal blood, it is grouped as by the group of following weight percent: sodium citrate 32%~38%, disodium ethylene diamine tetraacetate (EDTA-2Na) 18%~25%, sodium tripolyphosphate 15%~22%, benzoic acid or sodium benzoate 12%~18%, sodium Diacetate 8%~12%.Before use, being first dissolved in water, then added in every kilogram of blood using the ratio of 4~5 grams of the compound anti-coagulants of animal blood.Compound anti-coagulants of the invention is added to two kinds of preservatives of sodium Diacetate and sodium benzoate by experimental study, and optimizes and obtained optimal proportion relation, and under this conditions of mixture ratios, the effect of compound anti-coagulants is best: at low cost；Anticoagulant effect is good；Holding time is long.
Description
Technical field
The present invention relates to a kind of compound anti-coagulants of animal blood.
Background technique
Domestic animals blood processes comparative maturity at present, mainly by animal blood plasma after anticoagulant, by refrigeration
Preservation produces plasma protein powder and globulin powder after transporting back factory's separation, concentration and drying, and plasma protein powder is mainly used
In piglet preweaning feed, globulin powder is mainly used in aquatic products material and fowl material.The wherein added value highest of plasma protein powder,
But Feed Enterprise is stringenter to index requests such as plasma protein powder color, freshness, and the color of plasma protein powder and new
Freshness depends primarily on the effect quality of blood anti-coagulants used in collection process.
Blood processing enterprise generally divides pig blood and Qin Xue two types enterprise, their anti-coagulants is all variant: 1.
Pig blood processing enterprise generally uses pure sodium citrate or pure sodium tripolyphosphate as anti-coagulants, and this single anti-coagulants requires operation
Compare strictly, and have deviation in the blood quality that each meat producing plant is collected, the plasma protein powder color difference of output is larger.2.
Environment is poorer than pig blood collection environment, and substantially all Qin Xue manufacturing enterprises all use compound anti-coagulants because collecting for fowl blood,
But effect and cost are all barely satisfactory.
Based on the above situation, blood processing enterprise needs a kind of pair of blood anticoagulant time length at present and red blood cell is not easy haemolysis
With NEW TYPE OF COMPOSITE anti-coagulants at low cost.
Summary of the invention
For the above-mentioned prior art, the present invention provides a kind of compound anti-coagulants of animal blood, with good anticoagulant
Effect, and can effectively extend the holding time of animal blood.
The present invention is achieved by the following technical solutions:
A kind of compound anti-coagulants of animal blood, is grouped as by the group of following weight percent: sodium citrate 32%~38%,
Disodium ethylene diamine tetraacetate (EDTA-2Na) 18%~25%, sodium tripolyphosphate 15%~22%, benzoic acid or sodium benzoate
12%~18%, sodium Diacetate 8%~12%.
Preferably, it is grouped as by the group of following weight percent: sodium citrate 35%, disodium ethylene diamine tetraacetate 20%,
Sodium tripolyphosphate 20%, sodium benzoate 15%, sodium Diacetate 10%.
Preferably, it is grouped as by the group of following weight percent: sodium citrate 35%, disodium ethylene diamine tetraacetate 25%,
Sodium tripolyphosphate 15%, sodium benzoate 15%, sodium Diacetate 10%.
Further, the animal blood refers to chicken blood.
The compound anti-coagulants of animal blood of the invention, before use, (suitable ratio, such as 1:5~10) is first dissolved in water,
It is added again in every kilogram of blood using the ratio of 4~5 grams of the compound anti-coagulants of animal blood.
The principle of anti-coagulants is by anti-coagulants by the Ca in blood2+After chelating, Ca is prevented2+Fibrin ferment is activated, often at present
Calcium ion chelator has EDTA, sodium tripolyphosphate, sodium citrate etc..Compound anti-coagulants of the invention passes through experimental study,
Two kinds of preservatives of sodium Diacetate and sodium benzoate are added to, and optimizes and has obtained optimal proportion relation, under this conditions of mixture ratios,
The effect of compound anti-coagulants is best: (down to 7285 yuan/ton) at low cost；Anticoagulant effect is good；Holding time is long by (storable at least 4
It, not haemolysis).
The various terms and phrase that the present invention uses are with well known to a person skilled in the art general senses.The term referred to
With phrase if any meaning inconsistent with common art-recognized meanings, that the present invention of being subject to is stated.
Detailed description of the invention
Fig. 1: anti-coagulants colorimetric card schematic diagram.
Fig. 2: the anticoagulant effect schematic diagram of the compound anti-coagulants of 1#, 2#, 3# in experiment 1.
Fig. 3: the anticoagulant effect schematic diagram of the compound anti-coagulants of 4#, 5#, 6# in experiment 1.
Fig. 4: the anticoagulant effect schematic diagram in experiment 2 when compound anti-coagulants 24.
Fig. 5: the anticoagulant effect schematic diagram in experiment 2 when compound anti-coagulants 48.
Fig. 6: the anticoagulant effect schematic diagram in experiment 2 when compound anti-coagulants 72.
Fig. 7: the anticoagulant effect schematic diagram in experiment 2 when compound anti-coagulants 96.
Specific embodiment
Below with reference to embodiment, the present invention is further illustrated.However, the scope of the present invention is not limited to following realities
Apply example.One of skill in the art, can be to the present invention it is understood that under the premise of without departing substantially from the spirit and scope of the present invention
Carry out various change and modification.
The present invention carries out general and/or specific description to the material and test method arrived used in test.Though
So many materials and operating method used in purpose are it is known in the art that still the present invention is still herein to realize the present invention
It is described in detail as far as possible.
Instrument involved in following embodiments, reagent, material etc. are unless otherwise noted existing in the prior art
Conventional instrument, reagent, material etc., can be obtained by regular commercial sources.Experimental method involved in following embodiments, inspection
Survey method etc. is unless otherwise noted existing routine experiment method in the prior art, detection method etc..
Test the screening experiment of 1 compound anti-coagulants
By the compound anti-coagulants (group, which is grouped as, is shown in Table 1, and each component is by weight percentage) of 6 kinds of different ratios, by 1:10
Ratio be dissolved in the water, then, be added in every kilogram of chicken blood using the ratio of 5 grams of compound anti-coagulants just taken out it is new
In fresh poultry blood, observing effect (effect is defined the level by colorimetric card, and colorimetric card is as shown in Figure 1) after room temperature 48 hours, and
Analyze (EDTA-2Na:12000 yuan/ton of anti-coagulants cost；6500 yuan/ton of sodium tripolyphosphate；8000 yuan/ton of sodium benzoate；Double second
6000 yuan/ton of sour sodium；5100 yuan/ton of sodium citrate).
Table 1
As a result as shown in Figure 2 and Figure 3.As seen from the figure, 2#, 3#, 4#, 5# have obvious haemolysis, and 1#, 4# are existing without haemolysis
As (2 grades of colorimetric card), coagulating effectiveness is good.In view of cost, 1# cost performance is better than 4#, therefore, selects 1# as optimum proportioning,
And carry out following experiments.
Test the anticoagulant experiment of 2 compound anti-coagulants
By the compound anti-coagulants (group, which is grouped as, is shown in Table 2, and each component is by weight percentage) of 4 kinds of different ratios, by 1:10
Ratio be dissolved in the water, then, be added in every kilogram of chicken blood using the ratio of 5 grams of compound anti-coagulants just taken out it is new
In fresh poultry blood, the effect for 24 hours, after 48h, 72h, 96h (room temperature) is placed in observation (effect is defined the level by colorimetric card).
Table 2
| Number | Sodium citrate | Sodium tripolyphosphate | EDTA-2Na | Sodium benzoate | Sodium Diacetate |
| 1# | 100% | ||||
| 2# | 100% | ||||
| 3# | 10% | 25% | 50% | 10% | 5% |
| Newly | 35% | 20% | 20% | 15% | 10% |
As a result as also shown in e.g. figs. 4-7.As seen from the figure, the compound anti-coagulants of 1#, 2#, 3# just has apparent haemolysis existing after 24h
As, and new compound anti-coagulants is also able to maintain 2 grades of effects (1#, 2#, 3# haemolysis after 96 hours are 7 grades) after 96 hours, explanation
Compound anti-coagulants of the invention can preferably save blood, prevent haemolysis.
Above-described embodiment is provided to those skilled in the art, how to implement and use to be advocated with full disclosure and description
Embodiment, rather than for limiting range disclosed herein.Obvious modification will to those skilled in the art
Within the scope of the appended claims.
Claims (5)
1. a kind of compound anti-coagulants of animal blood, it is characterised in that: composed of the following components: sodium citrate 32%~38%, second
Edetate disodium 18%~25%, sodium tripolyphosphate 15%~22%, benzoic acid or sodium benzoate 12%~18%, double second
Sour sodium 8%~12%.
2. the compound anti-coagulants of animal blood according to claim 1, it is characterised in that: composed of the following components: citric acid
Sodium 35%, disodium ethylene diamine tetraacetate 20%, sodium tripolyphosphate 20%, sodium benzoate 15%, sodium Diacetate 10%.
3. the compound anti-coagulants of animal blood according to claim 1, it is characterised in that: composed of the following components: citric acid
Sodium 35%, disodium ethylene diamine tetraacetate 25%, sodium tripolyphosphate 15%, sodium benzoate 15%, sodium Diacetate 10%.
4. the compound anti-coagulants of animal blood described in any one of claim 1 to 3, it is characterised in that: the animal blood
The compound anti-coagulants of liquid is suitable for the anticoagulant of chicken blood and saves.
5. the application method of the compound anti-coagulants of animal blood according to any one of claims 1 to 4, it is characterised in that: first molten
Yu Shuizhong, then be added in blood in every kilogram of blood using the ratio of 4~5 grams of the compound anti-coagulants of animal blood.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910176976.7A CN109907170A (en) | 2019-03-08 | 2019-03-08 | A kind of compound anti-coagulants of animal blood |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910176976.7A CN109907170A (en) | 2019-03-08 | 2019-03-08 | A kind of compound anti-coagulants of animal blood |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109907170A true CN109907170A (en) | 2019-06-21 |
Family
ID=66963999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910176976.7A Pending CN109907170A (en) | 2019-03-08 | 2019-03-08 | A kind of compound anti-coagulants of animal blood |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109907170A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112841610A (en) * | 2021-01-12 | 2021-05-28 | 毕泽勋 | Pig blood anticoagulant fresh-keeping compound preparation and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100018436A1 (en) * | 2008-01-23 | 2010-01-28 | Sundaram Gunasekaran | Glue from slaughterhouse animal blood |
| CN101822312A (en) * | 2009-12-22 | 2010-09-08 | 安徽宝迪肉类食品有限公司 | Composite type animal blood anticoagulant agent |
| CN102058106A (en) * | 2010-12-14 | 2011-05-18 | 成都宏安生物科技有限公司 | Composite pig blood anticoagulant and use method thereof |
| CN102318837A (en) * | 2011-08-23 | 2012-01-18 | 安徽宝迪肉类食品有限公司 | Compound anticoagulant of animal blood |
| CN102907564A (en) * | 2011-08-05 | 2013-02-06 | 天津宝迪农业科技股份有限公司 | Preparation method and use method for compound type animal blood anticoagulant |
| CN109090438A (en) * | 2018-06-15 | 2018-12-28 | 南京黄教授食品科技有限公司 | A kind of fresh duck blood preparation and preservation method |
-
2019
- 2019-03-08 CN CN201910176976.7A patent/CN109907170A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100018436A1 (en) * | 2008-01-23 | 2010-01-28 | Sundaram Gunasekaran | Glue from slaughterhouse animal blood |
| CN101822312A (en) * | 2009-12-22 | 2010-09-08 | 安徽宝迪肉类食品有限公司 | Composite type animal blood anticoagulant agent |
| CN102058106A (en) * | 2010-12-14 | 2011-05-18 | 成都宏安生物科技有限公司 | Composite pig blood anticoagulant and use method thereof |
| CN102907564A (en) * | 2011-08-05 | 2013-02-06 | 天津宝迪农业科技股份有限公司 | Preparation method and use method for compound type animal blood anticoagulant |
| CN102318837A (en) * | 2011-08-23 | 2012-01-18 | 安徽宝迪肉类食品有限公司 | Compound anticoagulant of animal blood |
| CN109090438A (en) * | 2018-06-15 | 2018-12-28 | 南京黄教授食品科技有限公司 | A kind of fresh duck blood preparation and preservation method |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112841610A (en) * | 2021-01-12 | 2021-05-28 | 毕泽勋 | Pig blood anticoagulant fresh-keeping compound preparation and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tahvonen et al. | Lead and cadmium contents in pork, beef and chicken, and in pig and cow liver in Finland during 1991 | |
| CN102669411A (en) | Novel production process of high-quality plasma protein powder | |
| CN109907170A (en) | A kind of compound anti-coagulants of animal blood | |
| Camacho et al. | Evaluation of buffer solutions and urea addition for estimating the in vitro digestibility of feeds | |
| CN108690147B (en) | A kind of environmental type concentrated natural latex and preparation method thereof | |
| CN110760494B (en) | Preparation and application of urechis unicinctus autolytic enzyme | |
| CN109238927B (en) | Whole blood quality control substance and preparation method thereof | |
| CN109497045B (en) | Preservation solution and preparation method and application thereof | |
| Eun et al. | Addition of high concentration of inorganic selenium in orchardgrass (Dactylis glomerata L.) hay diet does not interfere with microbial fermentation in mixed ruminal microorganisms in continuous cultures | |
| CN113966737A (en) | Cell preservation solution for in vitro analysis and detection and preparation method thereof | |
| CN102907564A (en) | Preparation method and use method for compound type animal blood anticoagulant | |
| CN102058106A (en) | Composite pig blood anticoagulant and use method thereof | |
| CN110476951B (en) | Application of heparin sodium in preparation of diluent for cryopreservation of goat sperm and preparation method of heparin sodium | |
| CN110423713B (en) | Biological control method for postpartum mildew and rot disease of cherry and/or tomato fruits | |
| CN108002609A (en) | Salted egg salting feed liquid recycles and its method for cyclic process salted egg | |
| CN104072600A (en) | Blood anticoagulant | |
| US5556643A (en) | Anticoagulant compositions | |
| Hughes | Volatile amines of herring flesh | |
| US6423348B1 (en) | Anticoagulant compositions | |
| CN102265962A (en) | Novel anticoagulant for animal blood, and application thereof | |
| CN106387017B (en) | A kind of cold fresh pork nanometer fresh-keeping agent and preparation method thereof and preservation method | |
| CN1278632C (en) | Processing method for eliminating secondary sedimentation of concentrated apple juice | |
| Hill-Cottingham et al. | Absorption and breakdown of iron-ethylenediamine tetraacetic acid by tomato plants | |
| CN100537601C (en) | Method of extracting pig immunoglobulin IgG in pig blood | |
| US2932678A (en) | Process of preserving freshly harvested rubber latex |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190621 |